Related references
Note: Only part of the references are listed.Treatment of Fludarabine-refractory Chronic Lymphocytic Leukemia
Apostolia-Maria Tsimberidou et al.
CANCER (2009)
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL:: a prospective randomized HOVON trial
Edo Vellenga et al.
BLOOD (2008)
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia
Apostolia M. Tsimberidou et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal
Mazin A. Moufarij et al.
BLOOD (2006)
High-risk fludarabine-pretreated B-Cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission
Ignazio Majolino et al.
MEDICAL ONCOLOGY (2006)
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
MJ Keating et al.
BLOOD (2002)
Share Paper
